DBV Technologies (NASDAQ:DBVT - Free Report) had its price target lifted by HC Wainwright from $7.00 to $16.00 in a research report sent to investors on Monday, MarketBeat.com reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for DBV Technologies' Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.15) EPS, FY2026 earnings at ($0.85) EPS, FY2027 earnings at ($0.78) EPS, FY2028 earnings at ($0.37) EPS and FY2029 earnings at $0.37 EPS.
DBVT has been the subject of a number of other research reports. JMP Securities increased their target price on shares of DBV Technologies from $10.00 to $15.00 and gave the stock a "market outperform" rating in a research report on Thursday, May 1st. StockNews.com started coverage on DBV Technologies in a research report on Thursday, May 1st. They issued a "hold" rating on the stock.
View Our Latest Stock Analysis on DBV Technologies
DBV Technologies Stock Performance
NASDAQ:DBVT traded down $0.01 on Monday, hitting $9.83. The stock had a trading volume of 64,403 shares, compared to its average volume of 185,684. The stock has a market cap of $269.24 million, a P/E ratio of -2.18 and a beta of -0.66. The firm's fifty day simple moving average is $6.91 and its two-hundred day simple moving average is $4.87. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $10.12.
DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its earnings results on Friday, April 11th. The company reported ($1.10) EPS for the quarter. The business had revenue of $0.51 million for the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. Equities research analysts predict that DBV Technologies will post -7.05 EPS for the current year.
Hedge Funds Weigh In On DBV Technologies
An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC acquired a new position in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies as of its most recent filing with the Securities and Exchange Commission. 71.74% of the stock is currently owned by institutional investors and hedge funds.
About DBV Technologies
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Stories
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
